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Acute mountain sickness (AMS) is a debilitating health problem that affects a 
number of subjects when ascending to high altitude. Symptoms can include 
headache, nausea, lethargy, fatigue and subsequent loss of sleep and performance, 
however if susceptible subjects could be identified early precautionary measures 
could be put in place to reduce or eliminate AMS. The aim of this study was to 
determine if physiological variables measured at sea level could predict AMS (as 
measured by the Lake Louise score) at real altitude. A series of  physiological 
measures were taken at rest at sea level (Dunedin, New Zealand) and again at 
5050m (Pyramid Research Laboratory, Nepal). Measures included oxyhaemoglobin 
saturation, haematocrit, haemoglobin concentration, blood pressure, heart rate, 
cerebral blood flow and a number of ventilatory measures. We found that sea-level 
cerebral blood flow (R = 0.47), and haematocrit (R= -0.50) were strongly correlated 
with AMS, however using multiple linear regression results indicated that  sea-level 
mean blood pressure was the only statistically significant predictor of AMS at 
altitude (p < 0.01). This analysis indicated that sea-level mean blood pressure 
accounted for 45% of the prediction of AMS at altitude. In conclusion, while sea-level 
mean blood pressure is a useful predictor of AMS at altitude, clearly other factors 
account for the remaining 55% of AMS at altitude, and further research is required 
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The occurrence of acute mountain sickness (AMS) is a public health concern as about 
half of lowlanders develop symptoms after rapid ascent to altitude > 2500 m [1]. 
These symptoms, including headache, nausea, vomiting, anorexia, lethargy, fatigue, 
dizziness and insomnia, can be experienced to differing degrees with onset occurring 
between 6-10 h after arrival [1]. Knowledge of predictive factors responsible for this 
large inter-individual variation in AMS susceptibility would enable preventative 
strategies to be implicated.  
 
The occurrence of AMS has been shown to be related to previous acclimatisation to 
high altitude, rate of ascent and individual susceptibility [2-4]. The physiological 
responses which determine an individual’s susceptibility, however, remain 
debateable. A wide range of ventilatory, cardiovascular and cerebral variables have 
been recorded for the prediction of susceptibility to acute mountain sickness, 
however, as yet, no clear conclusion can be drawn [5, 6]. Moore et al. (1986) found 
individuals who develop AMS symptoms to simulated altitude (4,800 m for 4.5 h) 
have a lower hypoxic ventilatory response (HVR) compared with those that are 
asymptomatic. Further research, however, has been unable to replicate this finding 
[7-11]. The majority of the literature, involving both simulated [12-15] and real [16-
19] altitude exposures, of both prospective and retrospective design, suggest 
lowered SaO2 to be a good predictor of AMS susceptibility and AMS progression 
(reviewed in [5]). Several studies, however, have found no predictability of AMS 
susceptibility by SaO2 levels [20-22], although trends suggested greater O2 
desaturation in subjects exhibiting AMS [21, 22]. Further, Grant et al. (2002) found a 
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fairly poor correlation between SaO2 levels at simulated altitude (in the laboratory) 
and those found at a comparable real altitude. This finding would suggest 
correlations between SaO2 at simulated altitude and AMS may not necessarily occur 
upon ascent to real altitude. 
 
In addition to HVR and SaO2, physiological variables such as fluid retention [23], 
elevated intracranial pressure [24-26], elevated cerebral blood flow (CBF) [18], and 
impaired regulation of cerebral circulation [22] have been suggested to be related to 
the development of AMS. Further studies at simulated altitude (3800 – 4600 m), 
however, have reported no relationship between CBF and AMS susceptibility [12, 27-
29]. 
 
The majority of research on AMS susceptibility has focused on physiological 
responses upon exposure to simulated altitude (≤ 4600m) for short durations (30 
min – 6 h). As AMS symptoms may take longer to fully develop, and responses to 
simulated altitude may differ to those at real altitude, the current research aimed to 
identify physiological variables involved in the development of AMS upon ascent to 
the pyramid research laboratory, (5050 m), 4 km from Mt Everest base camp, Nepal.  
 
Aim of Study 
To determine if the symptoms of acute mountain sickness and the development of 
sleep apnea while breathing low levels of oxygen at sea-level can predict the extent 





Seventeen (11 males, 6 females) active, healthy individuals volunteered to 
participate in this study (Table 1), which was approved by the Lower South Otago 
Regional Ethics Committee and the Nepalese Research Council, and conformed to 
the standards set by the Declaration of Helsinki. Subjects were informed of the 
experimental procedures and possible risks involved in the study and written 
informed consent was obtained. Subjects had no history of cardiovascular, 
cerebrovascular or respiratory disease, were not taking medication and were non-
smokers. All subjects were sea-level residents and had not spent time at altitude in 
the preceding 6 months. 
 
Table 1 
Subject characteristics and LLAMS scores 
 
 Males Females All Subjects 
N 11 6 17 
Age (yr) 32±10 30±8 31±9 
Height (cm) 176.3±6.8 168.0±7.1 173.4±7.8 
Body Mass (kg) 72.3±7.8 61.8±5.9 68.6±8.7 
LLAMS score 2.9±3.4 4.5±1.4 3.5±2.2 
 
Experimental design 
In Dunedin, New Zealand, sea-level respiratory, cardiovascular and cerebrovascular 
measurements were obtained in normoxia (Partial Pressure of inspired O2 (PIO2) = 
140 mmHg) while resting in a reclined position. On arrival to Kathmandu, Nepal, the 
team of researchers and subjects ascended to the Pyramid Laboratory (5,050 m; PIO2 
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~74 mmHg) in the Khumbu Valley (4 km from Everest Base Camp). At the Pyramid 
Laboratory, the same measurements as were conducted at sea-level were repeated 
within 1-3 days of arrival. In addition, subjects completed the self-assessment 
section of the Lake Louise Consensus Altitude Mountain Sickness Scoring 
questionnaire (LLAMS) [30] regarding the occurrence of AMS symptoms. 
 
Respiratory measurements 
Tidal volume (VT), minute volume (VE) and respiratory frequency were measured 
with BREEZE Ex v3.06, Medical Graphics CPX/D Metabolic Cart (Medical Graphics, St. 
Paul, Minnesota, USA). 
 
CBF velocity, arterial BP and HR measurements 
CBF velocity was estimated by the measurement of middle cerebral artery blood 
flow velocity (MCAV) with a 2-MHz pulsed Doppler ultrasound system (DLW Doppler, 
Sterling, VA) and search techniques described elsewhere [31]. Beat-to-beat arterial 
BP was monitored with finger photoplethysmography (Finometer, TNO-TPD 
Biomedical Instrumentation) and mean arterial blood pressure (MBP) was calculated 
by [(2×diastolic)+systolic]/3. Cerebrovascular conductance (mean MCAV/MBP) and 
resistance (MBP/mean MCAV) were calculated. Heart rate was calculated from the 
BP waveform. All data were acquired continuously at 200 Hz with an analog-to-
digital converter (Powerlab/16SP ML795; ADInstruments). 
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Arterial blood measurements 
An arterial line was inserted into the radial artery and upon sampling, blood was 
immediately analysed (PaCO2, PaO2, SaO2, Hb, Hct, pH, HCO3
-) with a previously 
calibrated blood gas analyser (Radiometer ABL 500, Copenhagen, Denmark).  
 
Hypoxic responses 
Hypoxic ventilatory, cardiac and cerebral responses were calculated using the 
change in variables from SL to high altitude (day 1-3) as follows: 
Hypoxic ventilatory response (HVR) = ΔVE/ΔSaO2  
Hypoxic cardiac response (HCR) = ΔHR/ΔSaO2  
Cerebrovascular Response = ΔCBF/ΔPaCO2 
 
Statistical Analyses 
Data are presented as mean ± SD and analyses were conducted on SPSS (Version 15). 
Physiological changes from sea-level to altitude were analysed by paired t-tests. 
Simple linear regression was computed to locate variables most related to LLAMS 
score and the correlation matrix was studied for correlation between independent 
variables. This process resulted in the selection of 4 variables for further analyses. A 
multiple regression analysis, using a backwards elimination process, including 
quadratic transformation for the independent variable, was performed to determine 
the best subset of predictors of LLAMS score. Box-plots of these variable 
distributions were viewed for data normality. Log10 transformation of the dependent 
variable (LLAMS) resulted in no improvement of model fit.
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RESULTS 
Residence at high altitude (5,050 m) for 1-3 days significantly affected many systemic 
and cerebral variables compared to sea-level values (Table 2). HR and MBP were 
elevated at altitude compared with sea-level. VE was increased despite no significant 
change in either VT or Bf. An increase in CBF was found despite hyperventilatory 
induced hypocapnia (decreased respiratory and arterial CO2).  
Table 2 
Cardiovascular, cerebral, respiratory and blood gas variables measured at sea-level 
and at altitude (5,050 m) 
 
 Sea-level Altitude P 
HR (beats.min-1) 69±10 80±10 < 0.01 
MBP (mmHg) 78.5±14.0 89.8±15.0 <0.05 
CBF (cm.s-1) 66.3±10.9 84.1±16.0 <0.001 
CVC (cm.s-1.mmHg-1) 0.880±0.242 0.962±0.176 NS 
CVR (mmHg.cm-1.s-1) 1.233±0.382 1.096±0.260 NS 
VE (L.min
-1) 13.7±2.5 16.3±4.2 <0.05 
Vt (L) 1.0±0.3 1.0±0.3 NS 
Bf (breaths.min-1) 15.3±4.2 17.2±4.3 NS 
PO2 (mmHg) 108.7±8.1 47.2±5.8 <0.001 
PCO2 (mmHg) 40.8±4.5 25.6±2.9 <0.001 
SaO2 (%) 98.4±0.5 79.9±3.4 <0.001 
PaO2 (mmHg) 105.1±10.8 43.9±2.8 <0.001 
PaCO2 (mmHg) 41.5±3.1 29.2±2.6 <0.001 
pH 7.45±0.04 7.47±0.03 <0.05 
HCO3- (units??) 28.6±3.1 21.3±2.4 <0.001 
Hct (%) 43.7±4.0 45.7±3.9 <0.01 
Hb (g.dL-1??) 14.6±1.2 14.9±1.3 NS 




The increases in both MBP and CBF at altitude resulted in no change in CVC or CVR. A 
fall in SaO2 within the first few days at altitude accompanied the reduction in O2 
partial pressures (respiratory and arterial). Elevated arterial blood Hct at high 
altitude was not reflected by a change in Hb concentration. An increase in arterial pH 
with altitude exposure was found alongside a fall in arterial HCO3-. Altitude exposure 
for 1-3 days resulted in the development of AMS of varying degrees in the majority 
of participants, with only two individuals reporting no symptoms (range 0 – 7.5). 
Average LLAMS scores are reported in Table 1. Participant age and LLAMS score 
were not correlated. The LLAMS score was not related to CV response, HVR or 
plasma volume change, but was significantly correlated with HCR (R = -0.58, P = 
0.015). Of the sea-level measurements, MBP (Figure 1), CBF, CVC, CVR and Hct were 
found to be significantly correlated with LLAMS score (Table 3).  
 
Table 3 
Variables significantly correlated with LLAMS score selected for multiple linear 
regression and their correlation with LLAMS score (R) 
 
 Pearson Correlation 
R 
HCR -0.58* 
MBP (SL) -0.67** 
CBF (SL) 0.47* 
CVC (SL) 0.71** 
CVR (SL) -0.66** 
Hct (SL) -0.50* 
P < 0.05*, 0.01**,  SL = sea-level 
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As CVC and CVR were also highly correlated with both CBF (R = 0.77, -0.81, 
respectively) and MBP (R = -0.89, 0.86, respectively) at sea-level, these variables 
were removed from the multiple regression model to reduce collinearity. No 
variables measured at altitude were correlated with LLAMS score. Simple linear 
regression, therefore, identified the following variables as being highly correlated 
with LLAMS score and were chosen for the subsequent multiple regression analysis; 
HCR, CBF SL, MBP SL and Hct SL.  
 
Figure 1 
Relationship between AMS score and MBP at sea-level (SL) 
 
MBP SL (mmHg)


















The backward procedure isolated MBP SL as the only significant predictor of LLAMS 
score (Table 4). A quadratic transformation of MBP SL had little effect on the model 
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fit and was hence not included in the final analysis. MBP SL accounted for 45 % (R2 = 
0.448) of the prediction of LLAMS score.  
Table 4 
Multiple linear regression analysis of variables as predictors of LLAMS score 
 
 Variables Coefficient SE P 
Multiple Regression HCR -0.622 0.642 0.352 
(all variables) CBF SL 0.037 0.041 0.384 
 MBP SL -0.061 0.035 0.105 
 Hct SL -0.159 0.106 0.161 
Backwards Analysis MBP SL -0.105 0.030 0.003 
(best fit)     




Exposure to high altitude (5,050 m) for 1-3 days was found to affect several 
physiological variables and result in the development of AMS symptoms to varying 
degrees in the majority of subjects. The severity of AMS, as determined by the Lake 
Louise AMS scoring system, was best predicted by the measurement of MBP at sea-
level which accounted for 45 % of the prediction of AMS score. 
 
Exposure to high altitude for 1-3 days elevated both HR and MBP, with an increased 
sympathetic activity likely responsible for these changes. Although elevated HR at 
altitude is well documented [12, 13, 22, 27, 28, 32-35], few have concurrently 
reported an enhanced MBP [33, 34]. MBP appears to remain unchanged at altitude 
in the majority of studies [12, 22, 27, 28, 36]. Contrasting findings within the 
literature are potentially related to differing methodologies, including factors such as 
real versus simulated altitude, magnitude of elevation (m), rate of ascent and 
duration at altitude. Although a simulated altitude protocol was utilised by Sevre et 
al. (2001), the fact that they also reported elevated BP with increased altitude is 
potentially due to the stepwise increment in altitude over 3 days to an elevation of 
4500 m, similar to the real elevation in altitude in the present study. The other 
aforementioned studies either exposed subjects immediately to altitude (simulated) 
[12, 27, 28, 37] or ascent occurred faster than the present study (~ 1.5 days, [22]). A 
gradual rate of ascent has previously been shown to elevate HR to a greater level 
than an abrupt ascent (Vogel et al. 1967 – reviewed in [38]), a similar BP response 
may potentially occur. 
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Sea-level MBP was negatively correlated with AMS severity (R = -0.67, P < 0.01) and 
was the only significant predictor of AMS score. In contrast to the present finding, a 
significantly higher resting MBP at low altitude has been found in individuals 
susceptible to AMS (R = 0.5, P = 0.03) [21]. As the occurrence of AMS is well known 
to be influenced by the rate of ascent to altitude [4], with symptoms generally 
developing from 6 h of exposure [1], these differing findings may be due to a 
combination of slower rate of ascent and delayed recording of AMS symptoms (1-3 
days versus 2-4 h) upon arrival at altitude in the present study. A further possibility is 
that in the present study, AMS score was obtained from the self-reported section of 
the Lake Louise questionnaire, whereas, Lanfranchi et al. (2005) combined the self-
reported and clinical assessment sections. Although sea-level MBP was detected as 
the best predictor for AMS severity, it only accounted for ~ 45 % of AMS score, 
hence it is clear there are other factors involved in AMS susceptibility. 
 
AMS severity was not related to either sea-level or altitude HR or SaO2 values, 
however, when the fall in SaO2 at altitude was simultaneously considered with the 
change in HR, the hypoxic cardiac response was significantly correlated with AMS 
score (R = -0.58, P < 0.01), although it was not a significant predictor of AMS. In 
contrast, Leoppky et al. (2008) found HR at altitude (12 h at simulated altitude 
4880m) to be greater in those with the highest Lake Louise AMS scores compared 
with those with the lowest scores. Differing methodology between the two studies; 
real vs simulated altitude, rate of ascent to altitude, duration at altitude (24-72 h vs 
12 h); may explain these conflicting findings. Although the fall in SaO2 at altitude has 
previously been suggested to be the most useful predictor of AMS susceptibility [5, 
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12, 13], this is not supported by the current research or several earlier studies [20-
22]. This suggests that some factor other than the extent of hypoxaemia is 
responsible for the development of AMS. 
 
Resting CBF was elevated by 35.7% following 1-3 days exposure to high altitude (P < 
0.001). This elevation falls within the range reported (30-60%) upon acute ascent to 
~ 4000 m altitude [39], and is supported by many studies which have found an 
increase in CBF at altitude [28, 40]. There are, however, several reports of no change 
in CBF upon exposure to simulated [12, 27, 33] or real [22, 41] altitude. CBF change is 
dependent upon the sensitivity of the individual to hypoxic cerebral vasodilation and 
hypocapnic cerebral vasoconstriction, potentially explaining the varied CBF 
responses to altitude [39]. The elevation of MBP and CBF at altitude in the present 
study resulted in no change in either CVC or CVR upon altitude exposure. 
 
Resting CBF at sea-level was significantly correlated to AMS score (P < 0.05). This 
supports a previous finding that subjects exhibiting AMS symptoms (≥3 Lake Louise 
AMS scoring system) had a significantly higher resting CBF than those without AMS 
(0-2 Lake Louise score) [18]. Following further analysis (multiple regression with 
backward process), however, it became clear that, in the present study, CBF at sea-
level was not a significant predictor of AMS score. Altitude CBF was not related to 
severity of AMS, supportive of several publications [12, 22, 27, 29]. With the recent 
publication of data from 1985 [26], when Brian Cummins directly measured 
intracranial pressure at high altitude (5,030 m), it appears that the development of 
AMS may be dependent upon the compliance of the CBF systems and subsequent 
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accommodation of increased intracranial pressure upon exposure to high altitude. 
Less invasive research has recently supported the role of intracranial pressure in the 
development and severity of AMS by utilising the measurement of optic sheath 
diameter [24, 25]. The elevated CBF at altitude, therefore, appears to not be a 
predictor of AMS itself, but rather how the brain copes with the resulting increased 
intracranial pressure. In addition, impaired dynamic autoregulation of cerebral 
circulation has been found at real altitude [22, 41], which has been reported to be 
the only significant independent predictor of AMS severity (Environmental Symptom 
Questionnaire) [22]. 
 
A disturbance in plasma volume has previously been suggested to be related to AMS 
susceptibility (Ward et al. 2000 – In [42]). This is not supported by the current 
research where no change in PV was found, as determined by Hb and Hct data. The 
estimation of PV change in the present study, however, may not be as precise as the 
method adopted by Ward et al. (2000) (In [42]). 
 
The hyperventilatory-induced hypocapnia experienced during the first few days at 
high altitude was accompanied by a reduction in bicarbonate levels. This relationship 
has previously been reported [43], with an enhanced removal of excess base 
potentially occurring as a result of diuresis [44]. As the percentage fall in PaCO2 was 
greater than that of HCO3-, supportive of a previous finding [43], pH was increased 
at altitude, supportive of the literature [35]. 
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Despite a wide age range in our subjects (19 – 57yr), no correlation was found 
between AMS score and age, potentially due to our relatively low subject numbers. 
Conflicting results regarding the relationship between AMS score and age are 
presented in the literature. Lanfranchi et al. (2005) found older subjects to be more 
symptomatic, whereas Wagner et al. (2008) reported a negative correlation between 
age and AMS score, potentially due to brain atrophy and hence larger ventricles in 
the older individual allowing for improved protection upon increased intracranial 
pressure (reviewed in [26]). 
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CONCLUSIONS 
In summary, exposure to high altitude for 1-3 days affected many cardiorespiratory 
and cerebrovascular variables. Sea-level MBP, CBF and Hct, and HCR were strongly 
correlated with AMS score, however, sea-level MBP was the only significant 
predictor of AMS score (R2 = 0.448, P < 0.01). As the majority of the AMS score 
remained unpredicted, it is clear other variables, as not measured in the current 
research, are involved in the prediction of AMS susceptibility. Factors such as 
intracranial pressure and dynamic cerebral autoregulation may potentially be 
involved in the development of AMS at altitude. The measurement of these factors, 
however, involves specialised equipment and experienced individuals, and are, 
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